ScreenCell
ScreenCell is a French biotechnology company that commercializes a patented size-based microfiltration technology for isolating circulating tumor cells from whole blood, selling single-use consumable kits directly to academic, clinical, and pharmaceutical research customers across 30+ countries.
- Company typePrivate
- Founded2010
- HeadquartersSarcelles, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ScreenCell does
ScreenCell is a French biotechnology company founded in 2010 and headquartered in Besançon, France, that develops and commercializes a patented microfiltration technology for isolating circulating tumor cells (CTCs) from whole blood. The company's core technology isolates CTCs based on cell size differential using a membrane filtration approach, eliminating the need for immunological labeling, dedicated instrumentation, or biomarker-based capture. This marker-independent method is positioned to capture a broader spectrum of CTCs, including subpopulations that have undergone epithelial-mesenchymal transition (EMT) and exhibit reduced EpCAM expression, which antibody-based methods miss.
ScreenCell commercializes its technology through a portfolio of seven single-use CTC isolation kits (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) addressing cytology, molecular biology, and cell culture applications. The company sells these consumables directly to academic researchers, clinical laboratories, pharmaceutical and biotech companies, and healthcare providers through a website-based quote system and direct email contact, with no distribution intermediaries. As of January 2026, ScreenCell standardized its kit range to a 2 filtration unit / 1 dilution buffer format with eco-friendly packaging, operationalizing a '1 kit = 1 patient' workflow. The technology is validated across 16 cancer types, supported by 70+ peer-reviewed publications, and has been used in over 30 countries by customers including Mayo Clinic, MSKCC, AP-HP, INSERM, Institut Gustave Roussy, and the University of Manitoba. ScreenCell maintains an 11-50 employee operation and is governed by a leadership team including CEO Nicolas Schlumberger, CSO Georges Uzan, and CTO Sina Naserian.
ScreenCell firmographics
Firmographics- Name
- ScreenCell
- Legal name
- ScreenCell
- Website
- https://screencell.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ScreenCell is a French biotechnology company that commercializes a patented size-based microfiltration technology for isolating circulating tumor cells from whole blood, selling single-use consumable kits directly to academic, clinical, and pharmaceutical research customers across 30+ countries.
- Ownership category
- akta.pro rank
ScreenCell industry classification
Industry- Product category
- Liquid Biopsy / CTC Isolation Consumables
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)
- akta.pro secondary industry
- Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC)
Keywords
Where ScreenCell is headquartered
LocationHeadquarters
- HQ city
- Sarcelles
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
ScreenCell business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- CTC Isolation Kits: ScreenCell generates revenue through the sale of its single-use CTC isolation kits. The company offers 7 different kit variants (CYTO, CSB, FCD, FCD-SP, LCD, MB, MBSB) designed for different downstream applications including cytology, molecular biology, and cell culture. Kits are sold directly to researchers, clinicians, and laboratories without requiring distribution intermediaries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Custom quote-based pricing for CTC isolation kits |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels8 records
ScreenCell product offering
Product offeringCore offering
ScreenCell develops and manufactures single-use circulating tumor cell (CTC) isolation kits based on a patented, marker-independent microfiltration technology. The company sells 7 kit variants (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) designed for cytology, molecular biology, and cell culture downstream applications. Its products serve cancer researchers, clinical laboratories, and pharmaceutical companies globally.
Product overview
ScreenCell offers a suite of 7 single-use CTC isolation kits (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) all powered by a patented morphology-based microfiltration technology. The kits are organized into three application domains: Cytology (CYTO, CSB), Molecular Biology (FCD, FCD-SP, MB, MBSB, LCD), and Cell Culture (MB, MBSB). The CYTO and CSB kits fix CTCs on the isolation support for cytomorphological analysis; the MB and MBSB kits recover viable CTCs for 2D/3D cell culture and molecular analyses; and the FCD, FCD-SP, and LCD kits provide flexible recovery options in suspension or on slides for downstream molecular biology. The company also manufactures the filtration hardware (the ScreenCell device) that underpins all kits, which requires no dedicated instrumentation. In January 2026, ScreenCell is standardizing its entire kit range to 2 filtration units per kit with 1 dilution buffer.
Differentiator
Problem solved
Functional benefit
Brands
- CYTO kit: CTC isolation kit for cytology applications with fixed CTCs on isolation support, blood draw processed in under 4 hours.
- CSB kit
- FCD kit
- FCD-SP kit
- MB kit
- MBSB kit
- LCD kit
Products and services
- ScreenCell CYTO Kit CTC isolation kit for rapid processing of blood samples collected less than 4 hours prior. Fixed CTCs are recovered on the isolation support, enabling cytomorphological analysis, CTC enumeration, and downstream cytological applications including MGG staining, immunofluorescence, and immunocytochemistry. Designed for cancer researchers and clinical laboratories.
- ScreenCell CSB Kit CTC isolation kit optimized for blood samples processed between 4 hours and 3 days after collection, providing flexibility for samples with delayed handling. CTCs are recovered on the isolation support for downstream cytological analyses. Designed for cancer researchers and clinical laboratories handling batched or transported samples.
- ScreenCell FCD Kit CTC isolation kit that enables recovery of CTCs either in suspension or on a microscope slide, offering flexibility for different downstream molecular biology applications. Targets cancer researchers requiring adaptable sample output formats.
- ScreenCell FCD-SP Kit CTC isolation kit variant that transfers isolated cells onto a glass slide, enabling direct cytological examination and visualization of CTCs for downstream applications.
- ScreenCell MB Kit CTC isolation kit designed for the recovery of viable (live) CTCs from whole blood, enabling 2D and 3D cell culture, DNA and RNA extraction, and downstream molecular biology analyses including mutation detection (e.g., EGFR, KRAS) via ddPCR. Targets cancer researchers and translational scientists.
- ScreenCell MBSB Kit CTC isolation kit variant for recovery of viable CTCs with compatibility for molecular biology applications, supporting DNA and RNA extraction from enriched CTC samples for cell culture and downstream analysis.
- ScreenCell LCD Kit CTC isolation kit designed for liquid biopsy applications where CTCs are recovered in suspension, enabling downstream molecular biology analyses. Targets cancer researchers performing liquid biopsy workflows.
- ScreenCell® Microfiltration Technology Platform Patented morphology-based microfiltration technology platform for isolating circulating tumor cells (CTCs) and CTC clusters from whole blood of patients with solid tumors without immunological labeling. Validated across 16 cancer types including breast, lung, prostate, and colon cancers. Underpins the 7 ScreenCell CTC isolation kits.
Quantifiable outcome
- CTC enrichment in under 10 minutes
- +3 more outcomes
Companies that use ScreenCell
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
ScreenCell technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
ScreenCell partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core and minor.
- Paris Saclay Cancer Cluster (PSCC)coreScreenCell participates in the Paris Saclay Cancer Cluster, a private non-profit French scientific cooperation foundation dedicated to oncology innovation. Founded by Gustave Roussy, Sanofi, Inserm, Paris-Saclay University, and Institut Polytechnique de Paris, PSCC brings together key partners including Unicancer, Institut Curie, AP-HP, and Medicen covering the entire oncology value chain.
- Stand Up To Cancer (SU2C)minorScreenCell participates in the SU2C Scientific Summit 2026, a major oncology research event bringing together researchers and industry professionals to discuss the latest breakthroughs in cancer research.
- International Society for Liquid Biopsy (ISLB)coreScreenCell participates in ISLB's annual liquid biopsy conference, providing a platform to establish connections with North American and international thought leaders in liquid biopsy research and explore technological innovations.
- Advances in Circulating Tumor Cells (ACTC)minorScreenCell participates in the ACTC annual meeting focused on circulating tumor cell research.
- ISMRC (International Society for Mesenchymal Research on Cancer)minorScreenCell participates in ISMRC conferences to engage with the cancer research community.
- PMT SantécoreScreenCell joined PMT Santé (formerly Innov'Health cluster) based in Besançon, France. PMT Santé brings together industrial companies, research laboratories, and academic stakeholders in the health sector in the Bourgogne-Franche-Comté region. The cluster supports the French medical device industry and promotes regional excellence in health, focusing on medtech and biotech ecosystems including bioproduction.
- European Liquid Biopsy Society (ELBS)coreScreenCell became an industry member of ELBS, a scientific society founded in 2019 and chaired by Prof. Dr. med. Klaus Pantel from University Medical Center Hamburg-Eppendorf (UKE). ELBS brings together over 100 European partners from academia, clinical practice, and industry with the mission of advancing liquid biopsy research and accelerating its deployment in clinical practice.
- Sidney Kimmel Cancer Center at Thomas Jefferson UniversitycoreScreenCell entered a collaborative study with the Jefferson Breast Care Center at the Sidney Kimmel Cancer Center in Philadelphia to evaluate the effectiveness of ScreenCell's proprietary devices and protocols for enrichment of CTCs from peripheral blood in breast cancer patients. This collaboration addresses the limitation of EpCAM-dependent methods that miss 30-40% of metastatic breast cancer cases.
- Rouen University Hospital, Rome University Hospital-La Sapienza, University of Medicine and Pharmacy Cluj-NapocacoreResearchers at these institutions published a study in Cancer Biomarkers using the ScreenCell Cyto device to capture and characterize CTCs from colorectal cancer patients, demonstrating the technology's efficiency compared to immunomagnetic and microfluidic separation methods.
Scale indicators5 records
Recent moves8 records
Expansion highlights5 records
ScreenCell competitors and assessment
Company assessmentDirect peers
- Menarini Silicon Biosystems: Menarini Silicon Biosystems markets the FDA-cleared CELLSEARCH system, the clinical gold standard for CTC enumeration in metastatic breast, prostate, and colorectal cancer. Directly comparable to ScreenCell as both sell CTC isolation platforms to research and clinical oncology labs, though CellSearch is instrumented and ScreenCell is not.
- ANGLE plc: ANGLE's Parsortix system is a microfluidic, label-free CTC isolation platform used in research and clinical studies across multiple cancer types. Directly comparable in technology philosophy (microfluidic / size-based capture without antibodies) and customer base (translational oncology labs), competing for the same research-use budget.
- RareCyte: RareCyte offers an instrumented platform for CTC enumeration and single-cell retrieval from whole blood, used in academic and pharma research. Comparable to ScreenCell as a CTC-focused vendor serving translational oncology customers, though RareCyte's workflow relies on instrumentation and imaging rather than filtration alone.
Broad incumbents
- Miltenyi Biotec: Miltenyi Biotec is a major life-science tools vendor offering MACS-based cell separation, including positive/negative selection kits for CTC enrichment. Comparable as a broader incumbent in the cell-isolation space with overlapping research-customer base, though its core technology is antibody/magnetic-bead based rather than filtration.
- STEMCELL Technologies: STEMCELL Technologies supplies a broad portfolio of cell-separation and sample-preparation consumables for immunology, stem cell, and oncology research. Comparable as a life-science tools incumbent whose cell-isolation products compete for the same research budget as ScreenCell's CTC kits.
- QIAGEN: QIAGEN provides liquid-biopsy sample-preparation technologies (e.g., circulating nucleic-acid kits and CTC adjuncts) used by translational oncology labs. Comparable as a broad life-science tools incumbent whose products overlap the upstream sample-prep step of the same liquid-biopsy workflows ScreenCell serves.
- Bio-Techne: Bio-Techne (R&D Systems, ProteinSimple, ExoDx) sells proteomic and liquid-biopsy reagents to research and clinical labs. Comparable as a broad life-science tools vendor whose products and customer base (cancer researchers, clinical labs) overlap with ScreenCell's, though Bio-Techne is not CTC-specific.
Emerging players
- Biocept: Biocept offers liquid-biopsy services and proprietary CTC and ctDNA assays targeting oncology treatment selection and monitoring. Comparable as a CTC-focused emerging player, though Biocept's model is service-based (CLIA lab) rather than kit-based like ScreenCell.
- Apostle Sciences: Apostle develops liquid-biopsy technologies including CTC and ctDNA isolation reagents using magnetic nanoparticle and biochemical approaches. Comparable as an emerging CTC / liquid-biopsy reagent vendor targeting research and translational customers similar to ScreenCell.
- Canopy Biosciences (Bruker): Canopy Biosciences (part of Bruker) provides single-cell and spatial multi-omics platforms used in translational oncology research. Comparable as an emerging player whose single-cell technologies are an alternative analytical pathway for CTCs and tumor-cell characterization in the same research labs ScreenCell serves.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights6 records
Customer concentration
ScreenCell social profiles
Digital presenceScreenCell financial estimates
Financial estimateRevenue estimate
Valuation estimate
ScreenCell leadership team
Management profileNumber of profiles
Profiles4 records
ScreenCell funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ScreenCell M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ScreenCell
What does ScreenCell do?
ScreenCell develops and manufactures single-use circulating tumor cell (CTC) isolation kits based on a patented, marker-independent microfiltration technology. The company sells 7 kit variants (CYTO, CSB, FCD, FCD-SP, MB, MBSB, LCD) designed for cytology, molecular biology, and cell culture downstream applications. Its products serve cancer researchers, clinical laboratories, and pharmaceutical companies globally.
Is ScreenCell a public or private company?
ScreenCell is a private company. It is classified as venture growth investor backed and is currently operating.
When was ScreenCell founded?
ScreenCell was founded in 2010. It employs 11 to 50 people.
Where is ScreenCell based?
ScreenCell is headquartered in Sarcelles, France, in the Europe region.
How does ScreenCell make money?
One revenue line is on record: CTC Isolation Kits.
Who are ScreenCell's main competitors?
Direct peers on record are Menarini Silicon Biosystems, ANGLE plc and RareCyte. Broad incumbents are Miltenyi Biotec, STEMCELL Technologies, QIAGEN and Bio-Techne. Emerging players are Biocept, Apostle Sciences and Canopy Biosciences (Bruker).
Does ScreenCell have an API?
No public API is recorded for ScreenCell.
What industry is ScreenCell in?
ScreenCell's product category is Liquid Biopsy / CTC Isolation Consumables. Its primary akta.pro industry code is HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables), with a secondary code of HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization. Its NAICS code is 325413 and its SIC code is 2835.